791 related articles for article (PubMed ID: 24119623)
1. Incidence and cost of stroke and hemorrhage in patients diagnosed with atrial fibrillation in France.
Cotté FE; Chaize G; Kachaner I; Gaudin AF; Vainchtock A; Durand-Zaleski I
J Stroke Cerebrovasc Dis; 2014 Feb; 23(2):e73-83. PubMed ID: 24119623
[TBL] [Abstract][Full Text] [Related]
2. Bleeding as an outcome among patients with nonvalvular atrial fibrillation in a large managed care population.
Deitelzweig SB; Pinsky B; Buysman E; Lacey M; Makenbaeva D; Wiederkehr D; Graham J
Clin Ther; 2013 Oct; 35(10):1536-45.e1. PubMed ID: 24075151
[TBL] [Abstract][Full Text] [Related]
3. Burden of stroke and other cardiovascular complications in patients with atrial fibrillation hospitalized in France.
Cotté FE; Chaize G; Gaudin AF; Samson A; Vainchtock A; Fauchier L
Europace; 2016 Apr; 18(4):501-7. PubMed ID: 26718532
[TBL] [Abstract][Full Text] [Related]
4. Stroke prevention, 1-year clinical outcomes and healthcare resource utilization in patients with atrial fibrillation in France: Data from the GARFIELD-AF registry.
Le Heuzey JY; Bassand JP; Berneau JB; Cozzolino P; D'Angiolella L; Doucet B; Mantovani LG; Martelet M; Mouallem J; Muller JJ; Pieper K;
Arch Cardiovasc Dis; 2018 Dec; 111(12):749-757. PubMed ID: 29861295
[TBL] [Abstract][Full Text] [Related]
5. Impact of atrial fibrillation on stroke-related healthcare costs.
Sussman M; Menzin J; Lin I; Kwong WJ; Munsell M; Friedman M; Selim M
J Am Heart Assoc; 2013 Nov; 2(6):e000479. PubMed ID: 24275631
[TBL] [Abstract][Full Text] [Related]
6. Effect of Anticoagulation on Hospitalization Costs After Intracranial Hemorrhage in Atrial Fibrillation: A Registry Study.
Vestergaard AS; Skjøth F; Lip GY; Larsen TB
Stroke; 2016 Apr; 47(4):979-85. PubMed ID: 26883499
[TBL] [Abstract][Full Text] [Related]
7. The cost savings of newer oral anticoagulants in atrial fibrillation-related stroke prevention
.
Masbah N; Macleod MJ
Int J Clin Pharmacol Ther; 2017 Mar; 55(3):220-230. PubMed ID: 28025962
[TBL] [Abstract][Full Text] [Related]
8. The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation.
Roldán V; Marín F; Manzano-Fernández S; Gallego P; Vílchez JA; Valdés M; Vicente V; Lip GY
J Am Coll Cardiol; 2013 Dec; 62(23):2199-204. PubMed ID: 24055744
[TBL] [Abstract][Full Text] [Related]
9. Costs of major intracranial, gastrointestinal and other bleeding events in patients with atrial fibrillation - a nationwide cohort study.
Jakobsen M; Kolodziejczyk C; Klausen Fredslund E; Poulsen PB; Dybro L; Paaske Johnsen S
BMC Health Serv Res; 2017 Jun; 17(1):398. PubMed ID: 28606079
[TBL] [Abstract][Full Text] [Related]
10. All-cause and bleeding-related health care costs in warfarin-treated patients with atrial fibrillation.
Ghate SR; Biskupiak J; Ye X; Kwong WJ; Brixner DI
J Manag Care Pharm; 2011 Nov; 17(9):672-84. PubMed ID: 22050392
[TBL] [Abstract][Full Text] [Related]
11. Cost efficiency of anticoagulation with warfarin to prevent stroke in medicare beneficiaries with nonvalvular atrial fibrillation.
Mercaldi CJ; Ciarametaro M; Hahn B; Chalissery G; Reynolds MW; Sander SD; Samsa GP; Matchar DB
Stroke; 2011 Jan; 42(1):112-8. PubMed ID: 21148442
[TBL] [Abstract][Full Text] [Related]
12. Patients With Ischemic Stroke and Incident Atrial Fibrillation: A Nationwide Cohort Study.
Fauchier L; Clementy N; Pelade C; Collignon C; Nicolle E; Lip GY
Stroke; 2015 Sep; 46(9):2432-7. PubMed ID: 26251249
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: a French payer perspective.
Chevalier J; Delaitre O; Hammès F; de Pouvourville G
Arch Cardiovasc Dis; 2014; 107(6-7):381-90. PubMed ID: 24973113
[TBL] [Abstract][Full Text] [Related]
14. Risk of Ischemic Stroke in Patients With Atrial Fibrillation After Extracranial Hemorrhage.
Zhou E; Lord A; Boehme A; Henninger N; de Havenon A; Vahidy F; Ishida K; Torres J; Mistry EA; Mac Grory B; Sheth KN; Gurol ME; Furie K; Elkind MSV; Yaghi S
Stroke; 2020 Dec; 51(12):3592-3599. PubMed ID: 33028172
[TBL] [Abstract][Full Text] [Related]
15. Risk of hemorrhage and treatment costs associated with warfarin drug interactions in patients with atrial fibrillation.
Suh DC; Nelson WW; Choi JC; Choi I
Clin Ther; 2012 Jul; 34(7):1569-82. PubMed ID: 22717419
[TBL] [Abstract][Full Text] [Related]
16. The costs of warfarin underuse and nonadherence in patients with atrial fibrillation: a commercial insurer perspective.
Casciano JP; Dotiwala ZJ; Martin BC; Kwong WJ
J Manag Care Pharm; 2013 May; 19(4):302-16. PubMed ID: 23627576
[TBL] [Abstract][Full Text] [Related]
17. Using Phase-Based Costing of Real-World Data to Inform Decision-Analytic Models for Atrial Fibrillation.
Tawfik A; Wodchis WP; Pechlivanoglou P; Hoch J; Husereau D; Krahn M
Appl Health Econ Health Policy; 2016 Jun; 14(3):313-22. PubMed ID: 26924098
[TBL] [Abstract][Full Text] [Related]
18. Retrospective study of total healthcare costs associated with chronic nonvalvular atrial fibrillation and the occurrence of a first transient ischemic attack, stroke or major bleed.
Boccuzzi SJ; Martin J; Stephenson J; Kreilick C; Fernandes J; Beaulieu J; Hauch O; Kim J
Curr Med Res Opin; 2009 Dec; 25(12):2853-64. PubMed ID: 19916729
[TBL] [Abstract][Full Text] [Related]
19. Risk of stroke and intracranial hemorrhage in 9727 Chinese with atrial fibrillation in Hong Kong.
Siu CW; Lip GY; Lam KF; Tse HF
Heart Rhythm; 2014 Aug; 11(8):1401-8. PubMed ID: 24747420
[TBL] [Abstract][Full Text] [Related]
20. Incremental economic burden associated with major bleeding among atrial fibrillation patients treated with factor Xa inhibitors.
Deitelzweig S; Neuman WR; Lingohr-Smith M; Menges B; Lin J
J Med Econ; 2017 Dec; 20(12):1217-1223. PubMed ID: 28760063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
